| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Amitriptyline | Major depressive disorders and anxiety | Tablets | 10, 25, 50, 75 and 100 mg |
| Amitriptyline | Major depressive disorders and anxiety | XR tablets | 75 mg |
| Aripiprazole | Schizophrenia, bipolar disorder | Tablets | 5, 10, 15, 20 and 30 mg |
| Clomethiazole [S] | Insomnia, restlessness, agitation | Soft capsules | 192 mg |
| Clonazepam | Epilepsy | Oral drops, solution | 2.5 mg/ml |
| Clonazepam | Epilepsy | Tablets | 0.5 mg and 2 mg |
| Duloxetine | Major depressive disorders, neuropathic pain, anxiety | Gastro resistant hard capsules | 30 and 60 mg |
| Eslicarbazepine | Epilepsy | Film-coated tablets | 800 mg |
| Ethosuximide | Epilepsy, absence seizures | Soft capsules | 250 mg |
| Ethosuximide | Epilepsy, absence seizures | Oral solution | 50 mg/ml |
| Fampridine | Multiple sclerosis | XR tablets | 10 mg |
| Fingolimod | Multiple sclerosis | Capsules | 0.5 mg |
| Levetiracetam | Epilepsy | Film-coated tablets | 250, 500, 750 and 1000 mg |
| Levetiracetam | Epilepsy | Granules for oral solution | 250, 500, 750, 1000 and 1500 mg |
| Levetiracetam | Epilepsy | Oral solution | 100mg/ml |
| Levomethadone | Pain, opiod maintenance therapy | Oral solution | 5 mg/ml |
| Levomethadone | Pain, opiod maintenance therapy | Oral drops, solution | 5 mg/ml |
| Memantine hydrochloride | Alzheimer's disease | Film-coated tablets | 5, 10, 15 and 20 mg |
| Memantine hydrochloride | Alzheimer's disease | Oral solution | 10 mg/ml |
| Methocarbamol | Muscle spasms, pain | Film-coated tablets | 750 mg |
[S] Singular Generics
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.